Compare Citius Pharmaceuticals Inc (CTXR) vs Rubrik Inc. Class A Common Stock (RBRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Rubrik Inc. Class A Common Stock — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Rubrik Inc. Class A Common Stock trades at $125.14 (market cap $25.06B). The key difference: Rubrik Inc. Class A Common Stock is far larger — about 1839.9× Citius Pharmaceuticals Inc's market cap, and Rubrik Inc. Class A Common Stock is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Rubrik Inc. Class A Common Stock for 1 Days on average.
| CTXR | RBRK | |
|---|---|---|
Market Cap | $13.62M | $25.06B |
Volume | 132,438 | 2,394,852 |
Sector | Health | Technology |
52-Week High | $1.82 | $125.80 |
52-Week Low | $0.48 | $43.81 |
Typical Hold Time | 17 Days | 1 Days |
Enterprise Value | $3.79M | $24.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Rubrik Inc. Class A Common Stock
Rubrik provides data security and cyber recovery software for enterprises. Its platform protects data across on-premises, cloud, SaaS, and unstructured-data environments.
Read more on RBRK →
